MeiraGTx Holdings plc MGTX

Updated: 9 Aug 2026

NASDAQ | Biotech | Biotechnology / Gene Therapy

No signal published yet

We already track MeiraGTx Holdings and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow MeiraGTx Holdings free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Biotechnology / Gene Therapy
We're already tracking MeiraGTx Holdings plc — here are the latest events we've registered

Recent News

  • In July 2026, MeiraGTx entered into a strategic investment agreement with Oberland Capital for up to $400 million to support the development and commercialization of its gene therapy programs. The deal includes up to $375 million in non-dilutive capital in exchange for capped royalty payments and up to $25 million in equity investment.

What Firelda Watch includes for MeiraGTx Holdings plc

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of MeiraGTx Holdings plc will be delivered in the same format.

Want to follow MeiraGTx Holdings plc? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow MeiraGTx Holdings free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

MeiraGTx Holdings plc MGTX
MeiraGTx Holdings — follow and we'll monitor it
Follow MeiraGTx Holdings free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.